DM

Showing posts with label Protein. Show all posts
Showing posts with label Protein. Show all posts

Thursday, July 11, 2013

Study Shows Protein Complex May Play Role In Preventing Many Forms Of Cancer

Main Category: Cancer / Oncology
Also Included In: Genetics
Article Date: 08 May 2013 - 0:00 PDT Current ratings for:
Study Shows Protein Complex May Play Role In Preventing Many Forms Of Cancer
not yet ratednot yet rated
Researchers at the Stanford University School of Medicine have identified a group of proteins that are mutated in about one-fifth of all human cancers. The finding suggests that the proteins, which are members of a protein complex that affects how DNA is packaged in cells, work to suppress the development of tumors in many types of tissues.

The broad reach of the effect of mutations in the complex, called BAF, rivals that of another well-known tumor suppressor called p53. It also furthers a growing notion that these so-called chromatin-regulatory complexes may function as much more than mere cellular housekeepers.

"Although we knew that this complex was likely to play a role in preventing cancer, we didn't realize how extensive it would be," said postdoctoral scholar Cigall Kadoch, PhD. "It's often been thought that these complexes play supportive, maintenance-like roles in the cell. But this is really changing now."

Kadoch shares lead authorship of the study with postdoctoral scholar Diana Hargreaves, PhD. Gerald Crabtree, MD, professor of developmental biology and of pathology, is the senior author of the study, which was published online in Nature Genetics.

Chromatin-regulatory complexes work to keep DNA tightly condensed, while also granting temporary access to certain portions for replication or to allow the expression of genes necessary for the growth or function of the cell.

Members of Crabtree's laboratory have been interested in BAF complexes and their function for many years. Recently, they reported in the journal Nature that switching subunits within these complexes can convert human fibroblasts to neurons, which points to their instructive role in development and, possibly, cancer.

"Somehow these chromatin-regulatory complexes manage to compress nearly two yards of DNA into a nucleus about one one-thousandth the size of a pinhead," said Crabtree, who is also a member of the Stanford Cancer Institute and a Howard Hughes Medical Institute investigator. "And they do this without compromising the ability of the DNA to be replicated and selectively expressed in different tissues - all without tangling. In 1994 we reported that complexes of this type were likely to be tumor suppressors. Here we show that they are mutated in nearly 20 percent of all human malignancies thus far examined."

The researchers combined biochemical experiments with the data mining of 44 pre-existing studies to come to their conclusions, which would not have been possible without the advent of highly accurate, genome-wide DNA sequencing of individual human tumor samples. Interestingly, mutations to certain subunits, or particular combinations of mutations in the complex's many subunits, seem to herald the development of specific types of cancer - favoring the development of ovarian versus colon cancer, for example.

The importance of the BAF complex as a tumor suppressor is further emphasized by the fact that, in some cases, a mutation in one subunit is sufficient to initiate cancer development.

"For example," said Kadoch, "a type of mutation called a chromosomal translocation in the gene encoding one of these newly identified subunits, SS18, is known to be the hallmark of a cancer called synovial sarcoma. It is clearly the driving oncogenic event and very often the sole genomic abnormality in these cancers." Kadoch and Crabtree published a study in March in Cell uncovering the mechanism and functional consequences of BAF complex perturbation in synovial sarcoma.

The startling prevalence of mutations in the BAF complex was discovered when Kadoch conducted a series of experiments to determine exactly which proteins in the cell were true subunits of the complex. (The exact protein composition of the large complex varies among cell types and species.) Kadoch used an antibody that recognized one core component to purify intact BAF complexes in various cell types, including embryonic stem cells and skin, nerve and other cells. She then analyzed the various proteins isolated by the technique.

Using this method, Kadoch identified seven proteins previously unknown to be BAF components. She and Hargreaves then turned to previously published studies in which the DNA from a variety of human tumors had been sequenced to determine how frequently any of the members of the complex were mutated.

The results, once the newly discovered members were included, were surprising: 19.6 percent of all human tumors displayed a mutation in at least one of the complex's subunits. In addition, for some types of cancers (such as synovial sarcoma), every individual tumor sample examined had a mutation in a BAF subunit. The results suggest that the BAF complex, when unmutated, plays an important protective role against the development of cancer in many different tissues.

The researchers are now focused on learning how the mutations affect the tumor-suppressing activity of the BAF complex.

"We certainly want to further our understanding of the mechanism behind these findings," said Hargreaves. "Do they promote cancer development by inhibiting the proper progression of the cell cycle? Or perhaps they affect how the complex is positioned on the DNA. We'd like to determine how to recapitulate some of these mutations experimentally to see what types of defects they introduce into the complex."

Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our cancer / oncology section for the latest news on this subject. Other Stanford authors of the study include postdoctoral scholar Courtney Hodges, PhD, and former lab members Laura Elias, PhD, and Lena Ho, PhD.

The research was funded by the National Institutes of Health (grants NS046789, CA163915 and F32HD072627), the National Science Foundation, the Howard Hughes Medical Institute and the Helen Hay Whitney Foundation.

Stanford University Medical Center

Please use one of the following formats to cite this article in your essay, paper or report:

MLA

Stanford University Medical Center. "Study Shows Protein Complex May Play Role In Preventing Many Forms Of Cancer." Medical News Today. MediLexicon, Intl., 8 May. 2013. Web.
13 May. 2013. APA

Please note: If no author information is provided, the source is cited instead.


'Study Shows Protein Complex May Play Role In Preventing Many Forms Of Cancer'

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.



View the original article here

Monday, July 8, 2013

Protein Being Studied To Fight Cancer; May Cause Toxicity In Cardiac Cells

Main Category: Cardiovascular / Cardiology
Also Included In: Cancer / Oncology;??GastroIntestinal / Gastroenterology;??Heart Disease
Article Date: 19 Jun 2013 - 0:00 PDT Current ratings for:
Protein Being Studied To Fight Cancer; May Cause Toxicity In Cardiac Cells
not yet ratednot yet rated
A study by researchers at Skaggs School of Pharmacy and Pharmaceutical Sciences and the Department of Pharmacology at the University of California, San Diego, shows that a protein called MCL-1, which promotes cell survival, is essential for normal heart function.

Their study, published in th journal Genes & Development, found that deletion of the gene encoding MCL-1 in adult mouse hearts led to rapid heart failure within two weeks, and death within a month.

MCL-1 (myeloid cell leukemia-1) is an anti-apoptotic protein, meaning that it prevents or delays the death of a cell. It is also a member of the BCL-2 family of proteins that regulate mitochondria - the cell's power producers - and cell death. Aberrant expression of anti-apoptotic BCL-2 family members is one of the defining features of cancer cells, and is strongly associated with resistance to current therapies. Thus, these proteins are currently major targets in the development of new therapies for patients with cancer.

But, while MCL-1 is up regulated in a number of human cancers, contributing to the overgrowth of cancer cells, it is found at high levels in normal heart tissue. Additionally, the researchers found that autophagy - a process which deals with mitochondrial maintenance and is normally induced by myocardial stress - was impaired in mice with MCL-1 deficient hearts.

In summary, the study demonstrated that the loss of MCL-1 led to rapid dysfunction of mitochondria, impaired autophagy and heart failure, even in the absence of cardiac stress.

"Cardiac injury, such as a heart attack, causes levels of MCL-1 to drop in the heart, and this process may increase cardiac cell death," said Asa B. Gustafsson, PhD, an associate professor at UCSD Skaggs School of Pharmacy and Pharmaceutical Sciences. "Therefore, preserving normal levels of this protein in cardiac tissue could reduce damage after a heart attack and prevent progression to heart failure."

By compromising both autophagy and mitochondrial function, MCL-1 inhibitors are likely to affect the cells' energy supply. "Our findings raise concerns about the potential cardiac toxicity of drugs that block MCL-1 - drugs that have entered clinical trials because they increase cancer cell death," said the study's first author, Robert L. Thomas.

Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our cardiovascular / cardiology section for the latest news on this subject. Additional contributors to the paper include David J. Roberts, Dieter A. Kubli, Youngil Lee, Melissa N. Quinsay, Jarvis B. Owens and Shigeki Miyamoto, UC San Diego; and Kimberlee M. Fischer, Mark A. Sussman, San Diego State University.
The study was supported in part by grants from the National Institutes of Health (grants R01HL087023 and 715 R01HL101217).
University of California - San Diego Please use one of the following formats to cite this article in your essay, paper or report:

MLA

University of California - San Diego. "Protein Being Studied To Fight Cancer; May Cause Toxicity In Cardiac Cells." Medical News Today. MediLexicon, Intl., 19 Jun. 2013. Web.
24 Jun. 2013. APA

Please note: If no author information is provided, the source is cited instead.


'Protein Being Studied To Fight Cancer; May Cause Toxicity In Cardiac Cells'

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.



View the original article here

Sunday, July 7, 2013

Cancer Metastasis Promoted By Tumor-Activated Protein

Main Category: Cancer / Oncology
Article Date: 15 May 2013 - 1:00 PDT Current ratings for:
Cancer Metastasis Promoted By Tumor-Activated Protein
5 starsnot yet rated
Researchers at the University of California, San Diego School of Medicine and UC San Diego Moores Cancer Center report that cancers physically alter cells in the lymphatic system - a network of vessels that transports and stores immune cells throughout the body - to promote the spread of disease, a process called metastasis.

The findings are published in this week's online Early Edition of the Proceedings of the National Academy of Sciences.

Roughly 90 percent of all cancer deaths are due to metastasis - the disease spreading from the original tumor site to multiple, distant tissues and finally overwhelming the patient's body. Lymph vessels are often the path of transmission, with circulating tumor cells lodging in the lymph nodes - organs distributed throughout the body that act as immune system garrisons and traps for pathogens and foreign particles.

The researchers, led by principal investigator Judith A. Varner, PhD, professor of medicine at UC San Diego Moores Cancer Center, found that a protein growth factor expressed by tumors called VEGF-C activates a receptor called integrin α4β1 on lymphatic vessels in lymph node tissues, making them more attractive and sticky to metastatic tumor cells.

"One of the most significant features of this work is that it highlights the way that tumors can have long-range effects on other parts of the body, which can then impact tumor metastasis or growth," said Varner.

Varner said α4β1 could prove to be a valuable biomarker for measuring cancer risk, since increased levels of the activated protein in lymph tissues is an indirect indicator that an undetected tumor may be nearby.

She said whole-body imaging scans of the lymphatic network might identify problem areas relatively quickly and effectively. "The idea is that a radiolabeled or otherwise labeled anti-integrin α4β1 antibody could be injected into the lymphatic circulation, and it would only bind to and highlight the lymphatic vessels that have been activated by the presence of a tumor."

Varner noted that α4β1 levels correlate with metastasis - the higher the level, the greater the chance of the cancer spreading. With additional research and clinical studies, doctors could refine treatment protocols so that patients at higher risk are treated appropriately, but patients at lower or no risk of metastasis are not over-treated.

The researchers noted in their studies that it is possible to suppress tumor metastasis by reducing growth factor levels or by blocking activation of the α4β1 receptor. Varner said an antibody to VEGF-R3 is currently in Phase 1 clinical trials. An approved humanized anti-α4β1 antibody is currently approved for the treatment of multiple sclerosis and Crohn's disease. Varner said her lab at UC San Diego Moores Cancer Center is investigating the possibility of developing one for treating cancer.

Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our cancer / oncology section for the latest news on this subject. Co-authors include Barbara Garmy-Susini, Christie J. Avraamides, Michael C. Schmid and Philippe Foubert, UC San Diego Moores Cancer Center; Jay S. Desgrosellier, UC San Diego Moores Cancer Center and UCSD Department of Pathology; Lesley G. Ellies, Scott R. Vanderberg, Brian Datnow, Huan-You Wang and David A. Cheresh, UCSD Department of Pathology; Andrew M. Lowy and Sarah L. Blair, UC San Diego Moores Cancer Center and UCSD Department of Surgery.
Funding for this research came, in part, from National Institutes of Health grants CA83133 and CA126820; Department of Defense grant W81XWH-06-1-052 and NIH-National Cancer Institute grant U54 CA119335.
University of California - San Diego Please use one of the following formats to cite this article in your essay, paper or report:

MLA

University of California - San Diego. "Cancer Metastasis Promoted By Tumor-Activated Protein." Medical News Today. MediLexicon, Intl., 15 May. 2013. Web.
20 May. 2013. APA

Please note: If no author information is provided, the source is cited instead.


'Cancer Metastasis Promoted By Tumor-Activated Protein'

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.



View the original article here

Monday, June 3, 2013

Cancer-Suppressing Protein Found To 'Multitask'

Categorie principale : Cancer / oncologie
Egalement inclus dans : genetique
Date de l'article : 13 mai 2013 - 1:00 PDT courants nominaux pour :
Proteine suppresseur du cancer avere ? Multitache ?
not yet ratednot yet rated
La comprehension de la facon dont une puissante proteine appelee p53 protege contre le developpement du cancer a ete bouleversee par une decouverte par des chercheurs de l'Institut Walter et Eliza Hall.

Plus de la moitie des cancers humains portent des defauts dans le gene p53, et presque tous les autres cancers, avec un gene p53 normal, transporter d'autres defauts qui en quelque sorte portent atteinte a la fonction de la proteine p53. Herite de mutations du gene p53, mettre les gens a un tres haut risque de developper une gamme de cancers.

Fonctions de la proteine p53 sont normalement stimulees par potentiellement cancerigenes des evenements, tels que les dommages a l'ADN de rayonnement ultraviolet (une cause de cancer de la peau), ou la sur-activite des cancerigenes genes.

Mme Liz Valente, Dr Ana Janic et professeur Andreas Strasser de la division de genetique moleculaire du Cancer a l'Institut Walter et Eliza Hall ont ete disseque les processus controles par p53, pour decouvrir comment cette proteine peut supprimer le developpement du cancer. Leurs resultats surprenants sont publies en ligne dans la revue Cell Reports.

Dr Janic a dit que beaucoup de scientifiques croyait que les plus importants processus actives par p53 afin d'empecher la formation de cancer etaient arret cellules avec alteration de l'ADN de se diviser jusqu'a ce que l'ADN pouvait etre repare et rendant les cellules meurent s'ils avaient subi des dommages genetiques irreparable.

? Changements qui rendent les cellules endommagees deviennent longue duree de vie et de diviser de maniere incontrolee sont caracteristiques principales de la formation de cancer ?, a declare le Dr Janic. "Parce que p53 peut controler la survie cellulaire et la division cellulaire, on a suppose que ces deux processus constituaient les fonctions essentielles que p53 utilise pour prevenir le cancer. Le but de notre recherche etait d'examiner si cette hypothese etait correcte".

Mme Valente dit les cellules contre l'equipe qui n'avait pas de p53 avec cellules dans lequel p53 ne pouvait pas regler la survie cellulaire et la division cellulaire. "Dans les 20 dernieres annees qu'il est devenu clair quelles les proteines sont activees par p53 de bloquer la division cellulaire et de promouvoir la mort cellulaire,", a declare Mme Valente. "Nous avons pu supprimer tous ces proteines (appelees p21, Puma et Noxa) de cellules, de desactiver completement la possibilite de la p53 d'arreter la division cellulaire et declencher la mort des cellules. A notre grande surprise, p53 pourrait encore empecher la formation de cancer, meme sans etre en mesure de fabriquer des cellules meurent ou arreter divisant apres des dommages a l'ADN."

Professeur Strasser dit decouverte de l'equipe avait bouleverse la comprehension de la facon dont les fonctions p53. ? Lorsque le p53 suppresseur du cancer fonction a ete decouvert, qu'il etait important de comprendre le fonctionne de cette proteine, ? dit-il. ? Beaucoup de scientifiques avait conclu ce reglement de la division et la mort cellulaire ont ete les roles cles de p53, ? dit-il.

"Nos resultats ont rouvert la question de savoir comment les fonctions de p53. Mon soupcon est que ce n'est pas une proteine mais plusieurs avec de tres nombreuses fonctions critiques qui travaillent ensemble pour prevenir la formation de cancer par coordonner la bonne reparation de l'ADN endommage, plutot que de s'arreter de diviser ou de tuer les cellules. Autres recherches a dechiffrer comment ces processus sont integres sera une etape importante dans la comprehension de la fonction de suppresseur de tumeur p53 fonction. Ces connaissances, a son tour, puis peuvent etre exploitees pour developper des traitements ameliores,"a declare le professeur Strasser.

Article adapte par Medical News Today de communique de presse original. Cliquez sur ? references ? onglet ci-dessus pour la source.
Visitez notre cancer / oncologie section pour les dernieres nouvelles sur ce sujet. La recherche a ete financee par l'Australian National Health et Medical Research Council, la leucemie et Lymphoma Society (Etats-Unis), Cancer Council Victoria, The Lady Tata Memorial Trust, la bourse de Beatriu de Pinos (Union europeenne/Espagne) et le gouvernement de Victoria.
Walter et Eliza Hall Institute s'il vous plait utilisent un des formats suivants pour citer cet article dans votre essai, le papier ou le rapport :

MLA

Institut Walter et Eliza Hall. ? Proteine suppresseur du Cancer avere ? Multitache ?. ? Nouvelles medicales aujourd'hui. MediLexicon, aeroport international, 13 mai. 2013. Web.
13 Mai. 2013. APA

Veuillez noter : si aucune information de l'auteur est indiquee, la source est citee a la place.


? Proteine suppresseur du Cancer avere ' multitache ''

Veuillez prendre note que nous publions votre nom, mais nous ne publions pas votre adresse email. Il est seulement utilise pour vous avertir lorsque votre message est publie. Nous ne l'employons pas a d'autres fins. S'il vous plait voir notre politique de confidentialite pour plus d'informations.

Si vous ecrivez sur des medicaments specifiques ou les operations, s'il vous plait ne sont pas professionnels de la sante du nom par nom.

Tous les avis sont moderes avant d'etre inclus (pour arreter le spam)

Contactez nos redacteurs de News

Pour toutes les corrections d'informations factuelles, ou pour communiquer avec les editeurs, veuillez utiliser notre formulaire de commentaires.

Veuillez envoyer toute nouvelles medicales ou communiques de sante de presse a :

Note: des renseignements medicaux publies sur ce site ne sont pas concus comme un substitut a un avis medical eclaire et vous devriez prendre pas toute action avant de consulter des soins de sante professionnels. Pour plus d'informations, veuillez lire nos termes et conditions.



View the original article here